OKYO Pharma's Urcosimod Abstract Selected for Presentation at ARVO 2026
ByAinvest
Monday, Feb 23, 2026 11:02 am ET1min read
OKYO--
OKYO Pharma's abstract on urcosimod's efficacy in treating neuropathic corneal pain has been accepted for presentation at the ARVO 2026 Annual Meeting. The Phase 2a trial showed clinically meaningful pain reduction and quality-of-life improvement in NCP patients. Urcosimod is a non-opioid, preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity. The company plans to initiate a ~150 subject Phase 2b/3 multiple-dose study in the first half of this year.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet